Momelotinib is also type-I JAK1/2 specific inhibitor, similar to ruxolitinib, that was expected to improve symptoms of therapy-induced anemia by also inhibiting activin A receptor type 1 (ACVR1) (Asshoff et al., 2017). This evidence concerns the gene ACVR1 and anemia.